Samuel R Saks is Chief Medical Officer of Protagonist Therapeutics, Inc. Currently has a direct ownership of 14,000 shares of PTGX, which is worth approximately $588,280. The most recent transaction as insider was on Feb 26, 2021, when has been sold 12,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 14K
0% 3M change
0% 12M change
Total Value Held $588,280

Samuel R Saks Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 26 2021
BUY
Grant, award, or other acquisition
-
12,000 Added 46.15%
14,000 Common Stock
SRS

Samuel R Saks

Chief Medical Officer
Newark, CA

Track Institutional and Insider Activities on PTGX

Follow Protagonist Therapeutics, Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTGX shares.

Notify only if

Insider Trading

Get notified when an Protagonist Therapeutics, Inc insider buys or sells PTGX shares.

Notify only if

News

Receive news related to Protagonist Therapeutics, Inc

Track Activities on PTGX